EGFR mutant-selective inhibitor BPI-361175

{
  "id": "MLC-T-ONC-013256",
  "term": "EGFR mutant-selective inhibitor BPI-361175",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable, mutant-selective, fourth-generation epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, EGFR mutant-selective inhibitor BPI-361175 targets, binds to and inhibits the activity of EGFR with C797S and other related mutations, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. BPI-361175 inhibits mutated forms of EGFR with C797S and other related mutations that are resistant to third-generation EGFR inhibitors.",
  "synonyms": [
    "EGFR inhibitor BPI-361175",
    "EGFR TKI BPI-361175"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/egfr-mutant-selective-inhibitor-bpi-361175/"
}